PANIC
MCID: PNC025
MIFTS: 53

Panic Disorder (PANIC)

Categories: Mental diseases, Neuronal diseases, Respiratory diseases

Aliases & Classifications for Panic Disorder

MalaCards integrated aliases for Panic Disorder:

Name: Panic Disorder 12 74 36 54 42 43 15 17 71
Panic Anxiety Syndrome 12
Panic Disorder 1 71
Panic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:594
KEGG 36 H01664
MeSH 43 D016584
NCIt 49 C34890
SNOMED-CT 67 371631005
ICD10 32 F41.0
UMLS 71 C0030319 C1868649

Summaries for Panic Disorder

KEGG : 36 Panic disorder (PD) is a common type of anxiety disorder, characterized by unexpected and repeated panic attacks or fear of future panic attacks. It has a rapid onset and includes symptoms such as palpitations, chest pain, sweating and shaking. Some physical illnesses (e.g. asthma) commonly occur with panic disorder, and certain lifestyle factors (e.g. smoking) increase the risk for the disorder, but causal pathways are still unclear. In recent years, an association was found between panic symptoms and increased activity in the right frontal region of the brain. Genetic susceptibility factors also exist, but their exact nature and pathophysiological mechanisms remain unknown. Cognitive behavioural therapy (CBT) and several medications, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and benzodiazepines are effective for PD. Among these, SSRIs and SNRIs are considered to be first-line treatment agents because of their efficacy and favorable side effect profile.

MalaCards based summary : Panic Disorder, also known as panic anxiety syndrome, is related to panic disorder 1 and panic disorder 2. An important gene associated with Panic Disorder is MIR22 (MicroRNA 22), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Etoricoxib and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by unexpected and repeated episodes of intense fear accompanied by physical symptoms that may include chest pain, heart palpitations, shortness of breath, dizziness, or abdominal distress.

MedlinePlus : 42 Panic disorder is a type of anxiety disorder. It causes panic attacks, which are sudden feelings of terror when there is no real danger. You may feel as if you are losing control. You may also have physical symptoms, such as Fast heartbeat Chest or stomach pain Breathing difficulty Weakness or dizziness Sweating Feeling hot or a cold chill Tingly or numb hands Panic attacks can happen anytime, anywhere, and without warning. You may live in fear of another attack and may avoid places where you have had an attack. For some people, fear takes over their lives and they cannot leave their homes. Panic disorder is more common in women than men. It usually starts when people are young adults. Sometimes it starts when a person is under a lot of stress. Most people get better with treatment. Therapy can show you how to recognize and change your thinking patterns before they lead to panic. Medicines can also help. NIH: National Institute of Mental Health

Wikipedia : 74 Panic disorder is an anxiety disorder characterized by reoccurring unexpected panic attacks. Panic... more...

Related Diseases for Panic Disorder

Diseases in the Panic Disorder family:

Panic Disorder 1 Panic Disorder 2
Panic Disorder 3

Diseases related to Panic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 454)
# Related Disease Score Top Affiliating Genes
1 panic disorder 1 35.3 PAND1 COMT
2 panic disorder 2 34.9 PTK7 PAND2
3 anxiety 33.3 TSPO TPH2 SLC6A4 SLC6A2 PTK7 MAOA
4 neurotic disorder 33.3 SLC6A4 MAOA HTR2A HTR1A
5 major depressive disorder 33.1 TPH2 SLC6A4 SLC6A2 MAOA HTR3A HTR2A
6 obsessive-compulsive disorder 33.1 TPH2 SLC6A4 PTK7 MAOA HTR3A HTR2A
7 agoraphobia 32.6 SLC6A4 SLC6A2 PTK7 MIR22 MAOA HTR2A
8 schizophrenia 32.5 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR3A
9 depression 32.4 TPH2 SLC6A4 MAOA HTR2A HTR1A CRH
10 social phobia 32.2 SLC6A4 PTK7 MAOA HTR3A HTR1A COMT
11 generalized anxiety disorder 32.2 TSPO SLC6A4 SLC6A2 MAOA HTR3A HTR2A
12 mental depression 32.1 TPH2 SLC6A4 SLC6A2 MAOA HTR3A HTR2A
13 personality disorder 31.9 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
14 substance abuse 31.8 SLC6A4 MAOA HTR2A HTR1A CRH COMT
15 alcohol use disorder 31.7 SLC6A4 HTR3A HTR2A HTR1A CRH COMT
16 phobia, specific 31.7 SLC6A4 MAOA HTR1A CRH COMT
17 alexithymia 31.7 SLC6A4 HTR1A COMT
18 dysthymic disorder 31.7 SLC6A4 MAOA HTR2A HTR1A CRH
19 avoidant personality disorder 31.7 SLC6A4 MAOA
20 hypochondriasis 31.7 SLC6A4 HTR3A HTR2A HTR1A
21 mood disorder 31.7 TPH2 SLC6A4 SLC6A2 MAOA HTR3A HTR2A
22 somatization disorder 31.6 SLC6A4 HTR2A CRH
23 eating disorder 31.6 SLC6A4 HTR2A CRH COMT CCK
24 sexual disorder 31.5 SLC6A4 HTR3A HTR2A HTR1A
25 phobic disorder 31.5 SLC6A4 MAOA HTR2A HTR1A CRH COMT
26 irritable bowel syndrome 31.5 SLC6A4 HTR3A HTR2A HTR1A CRH COMT
27 withdrawal disorder 31.5 TSPO HTR1A CRH
28 endogenous depression 31.5 SLC6A4 MAOA HTR3A HTR2A HTR1A CRH
29 alcohol dependence 31.4 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR3A
30 post-traumatic stress disorder 31.4 SLC6A4 MAOA HTR2A HTR1A CRH COMT
31 bipolar disorder 31.3 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR3A
32 sleep disorder 31.3 SLC6A4 HTR2A HTR1A
33 migraine with or without aura 1 31.3 SLC6A4 MAOA HTR3A HTR2A HTR1A CRH
34 substance dependence 31.3 SLC6A4 MAOA CRH COMT
35 obsessive-compulsive personality disorder 31.2 SLC6A4 HTR2A COMT
36 bulimia nervosa 31.2 SLC6A4 MAOA HTR3A HTR2A CRH COMT
37 borderline personality disorder 31.2 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
38 bipolar i disorder 31.2 TPH2 SLC6A4 HTR2A HTR1A COMT
39 somatoform disorder 31.1 SLC6A4 HTR3A CRH COMT
40 constipation 31.1 SLC6A4 SLC6A2 HTR3A HTR2A HTR1A CCK
41 body dysmorphic disorder 31.1 SLC6A4 MAOA HTR2A
42 attention deficit-hyperactivity disorder 31.1 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR2A
43 fibromyalgia 31.0 TSPO SLC6A4 HTR3A HTR2A HTR1A CRH
44 acute stress disorder 31.0 SLC6A4 CRH
45 tobacco addiction 31.0 SLC6A4 MAOA HTR2A CRH COMT
46 amnestic disorder 31.0 TSPO HTR3A HTR1A
47 adjustment disorder 30.9 TSPO SLC6A4 HTR2A HTR1A
48 cyclothymic disorder 30.9 HTR2A COMT
49 melancholia 30.9 SLC6A4 MAOA HTR2A HTR1A CRH
50 premature ejaculation 30.9 SLC6A4 HTR3A HTR1A COMT

Graphical network of the top 20 diseases related to Panic Disorder:



Diseases related to Panic Disorder

Symptoms & Phenotypes for Panic Disorder

GenomeRNAi Phenotypes related to Panic Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.28 SLC6A4
2 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
4 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A

MGI Mouse Phenotypes related to Panic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 CCKAR CCKBR COMT CRH HTR1A HTR2A
2 homeostasis/metabolism MP:0005376 9.93 CCK CCKAR CCKBR COMT CRH HTR1A
3 endocrine/exocrine gland MP:0005379 9.91 CCK CCKAR CCKBR COMT CRH HTR2A
4 nervous system MP:0003631 9.73 CCK CCKAR CCKBR COMT CRH HTR1A
5 renal/urinary system MP:0005367 9.17 CCK CCKAR CCKBR COMT CRH HTR3A

Drugs & Therapeutics for Panic Disorder

Drugs for Panic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
2
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Propranolol Approved, Investigational Phase 4 525-66-6 4946
5
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
6
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
7
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
8
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
9
Clozapine Approved Phase 4 5786-21-0 2818
10
Ziprasidone Approved Phase 4 146939-27-7 60854
11
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
12
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
13
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
14
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
15
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
16
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
17
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
18
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
19
Promethazine Approved, Investigational Phase 4 60-87-7 4927
20
Suvorexant Approved, Investigational Phase 4 1030377-33-3
21
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
22
Sertraline Approved Phase 4 79617-96-2 68617
23
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
24 Cyclooxygenase Inhibitors Phase 4
25 Cyclooxygenase 2 Inhibitors Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Antirheumatic Agents Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Psychotropic Drugs Phase 4
30 Neurotransmitter Agents Phase 4
31 Anesthetics Phase 4
32 Anesthetics, General Phase 4
33 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
34 Duloxetine Hydrochloride Phase 4
35 Analgesics Phase 4
36 Adrenergic beta-Antagonists Phase 4
37 Antihypertensive Agents Phase 4
38 Adrenergic Agents Phase 4
39 Adrenergic Antagonists Phase 4
40 Anti-Arrhythmia Agents Phase 4
41 Quetiapine Fumarate Phase 4 111974-72-2
42 Antipsychotic Agents Phase 4
43 Serotonin 5-HT1 Receptor Agonists Phase 4
44 Serotonin 5-HT3 Receptor Antagonists Phase 4
45 Dopamine Antagonists Phase 4
46 Dopamine agonists Phase 4
47 Contraceptive Agents Phase 4
48 Contraceptives, Oral Phase 4
49 Excitatory Amino Acid Antagonists Phase 4
50 Anesthetics, Dissociative Phase 4

Interventional clinical trials:

(show top 50) (show all 378)
# Name Status NCT ID Phase Drugs
1 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
2 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
3 A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
4 Phase 4 Study of Panic Disorder That Expresses to Change of Cerebral Glucose Metabolism After 12 Week of Paroxetine Treatment Completed NCT00767754 Phase 4 Paxil CR
5 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder Completed NCT00438971 Phase 4 Duloxetine
6 Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
7 Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
8 A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
9 The Effects of Treatment With Sertraline for Panic Disorder and/or Depression Driven Chest Pain and/or Palpitations in a Double Blind, Care as Usual and Placebo Controlled Study Completed NCT01114100 Phase 4 sertraline;placebo
10 An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder Completed NCT00619892 Phase 4 quetiapine XR;placebo
11 A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder Completed NCT02395510 Phase 4 Vortioxetine
12 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
13 Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters Completed NCT00438386 Phase 4 Aripiprazole
14 Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial Completed NCT00803400 Phase 4 Alprazolam;Alprazolam + Aerobic exercise
15 Combined Treatment With A Benzodiazepine (Clonazepam) And A Selective Serotonin Reuptake Inhibitor (Paroxetine) For Rapid Treatment Of Panic Disorder With Depression Completed NCT00031317 Phase 4 Paroxetine;Clozapine
16 A Randomized Double-Blind Comparison of Sertraline With Early Alprazolam XR Co-Administration vs Sertraline/Placebo for Primary Care Panic Disorder Patients Completed NCT00198094 Phase 4 Sertraline and Alprazolam XR
17 A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
18 Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
19 A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder Completed NCT01172652 Phase 4 Ziprasidone;Placebo
20 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
21 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Completed NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
22 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients (MOSAIC) Completed NCT01201967 Phase 4
23 A Randomized Controlled Trial of Cognitive Behavioural Therapy for Non-cardiac Chest Pain and Palpitations. Completed NCT00623454 Phase 4
24 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
25 Investigation of Genetic Predictors of the Response to SSRI Treatment Completed NCT03927950 Phase 4 escitalopram;bupropion
26 Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders Completed NCT02579928 Phase 4 Ketamine;Midazolam
27 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
28 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
29 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
30 Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
31 Pharmacotherapy in Depression With Panic Spectrum Completed NCT00177996 Phase 4 sertraline hydrochloride
32 Cannabinoid Control of Fear Extinction Neural Circuits in Humans Completed NCT02472847 Phase 4 Dronabinol;Placebo
33 Psychophysiology of Delayed Extinction and Reconsolidation in Humans Completed NCT01631682 Phase 4 Propranolol;Mifepristone;Intranasal oxytocin
34 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Recruiting NCT03522844 Phase 4 Escitalopram
35 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
36 A Pragmatic Randomized Comparator Trial of Eszopiclone and Brief Behavioral Therapy for Insomnia in CPAP Non Adherent Veterans With PTSD and Complex Insomnia Recruiting NCT03937713 Phase 4 eszopiclone
37 The Role of Orexin in Human Panic Disorder Active, not recruiting NCT02593682 Phase 4 suvorexant;placebo
38 Effects of Perampanel on Neurophysiology Test Perimeters Suspended NCT03653741 Phase 4 Perampanel 6 MG
39 An Open-Label Study to Assess the Safety and Tolerability of Xanax XR in the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
40 A Randomized, Double-Blind, Placebo-Controlled Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder Terminated NCT00635531 Phase 4 alprazolam XR
41 A Randomized, Double-Blind, Placebo-Controlled Study of Continuation Treatment With Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder Terminated NCT00635076 Phase 4 alprazolam XR
42 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
43 Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure Unknown status NCT01323556 Phase 2, Phase 3
44 A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder Completed NCT00038896 Phase 3 Venlafaxine ER
45 A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder Completed NCT00044772 Phase 3 Venlafaxine ER
46 Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine. Completed NCT00195598 Phase 3 VENLAFAXINE;Paroxetine
47 Randomized Controlled Trial of Psychodynamic Psychotherapy vs. Applied Relaxation for Panic Disorder Completed NCT00128388 Phase 2, Phase 3
48 Treatment Refractory Panic Disorder Completed NCT00118417 Phase 2, Phase 3 Clonazepam;Sertraline
49 Internet- Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder in a Psychiatric Setting: A Randomized Equivalence Trial Completed NCT00845260 Phase 3
50 A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3

Search NIH Clinical Center for Panic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Clomipramine
Clomipramine Hydrochloride
Clonazepam
Diazepam
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Maprotiline
Maprotiline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Propranolol
Propranolol Hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam

Cochrane evidence based reviews: panic disorder

Genetic Tests for Panic Disorder

Anatomical Context for Panic Disorder

MalaCards organs/tissues related to Panic Disorder:

40
Brain, Heart, Testes, Amygdala, Cortex, Thyroid, Pituitary

Publications for Panic Disorder

Articles related to Panic Disorder:

(show top 50) (show all 9003)
# Title Authors PMID Year
1
In vivo investigation on bio-markers of perimenopausal panic disorder and catgut embedding acupoints mechanism. 42 61
32384434 2020
2
Treatment-related changes towards normalization of the abnormal external signal processing in panic disorder. 42 61
31986163 2020
3
Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. 61 46
21168126 2011
4
Anxiety and Fear-Related Disorders in the ICD-11: Results from a Global Case-controlled Field Study. 42
32018071 2019
5
Platelet serotonin transporter function and heart rate variability in patients with panic disorder. 61 54
20358007 2010
6
Gene variations in the cholecystokinin system in patients with panic disorder. 61 54
20023595 2010
7
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. 54 61
18574484 2010
8
Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder. 54 61
19969287 2010
9
Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). 54 61
18663369 2010
10
CCK as a modulator of cardiovascular function. 61 54
19563885 2009
11
The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. 54 61
19683026 2009
12
Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone concentrations. 61 54
19501468 2009
13
The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. 54 61
19289240 2009
14
779 TC of CCK-1 intron 1 is associated with postprandial syndrome (PDS) in Japanese male subjects. 61 54
19760980 2009
15
Effects of experimentally induced panic attacks on neuroimmunological markers. 54 61
19023641 2009
16
Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia. 54 61
18629431 2009
17
Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4. 54 61
18534623 2009
18
Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers. 61 54
18832011 2008
19
The association between serotonin-related gene polymorphisms and panic disorder. 61 54
18436425 2008
20
Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. 54 61
18384079 2008
21
Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. 54 61
18440204 2008
22
Platelet 18 kDa Translocator Protein density is reduced in depressed patients with adult separation anxiety. 54 61
18054208 2008
23
Respiratory irregularity and stress hormones in panic disorder: exploring potential linkages. 61 54
17557312 2008
24
Lack of association between the serotonin transporter promoter polymorphism (5-HTTLPR) and personality traits in asymptomatic patients with panic disorder. 61 54
18164547 2008
25
Lack of association between the Serotonin Transporter Promoter Polymorphism (5-HTTLPR) and Panic Disorder: a systematic review and meta-analysis. 61 54
17705872 2007
26
Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor. 61 54
17613943 2007
27
Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. 54 61
17318504 2007
28
Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. 54 61
17357147 2007
29
Reduced serotonin-1A receptor binding in social anxiety disorder. 54 61
16979141 2007
30
Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. 54 61
17123728 2007
31
HPA axis activity in patients with panic disorder: review and synthesis of four studies. 61 54
16845643 2007
32
Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. 61 54
16822601 2006
33
Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. 54 61
16525418 2006
34
The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. 54 61
16401665 2006
35
The neuronal noradrenaline transporter, anxiety and cardiovascular disease. 61 54
16785272 2006
36
Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. 61 54
16600640 2006
37
Cholecystokinin hyperresponsiveness in functional dyspepsia. 61 54
16718754 2006
38
Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. 61 54
16541242 2006
39
Evidence that variation in the peripheral benzodiazepine receptor (PBR) gene influences susceptibility to panic disorder. 54 61
16511838 2006
40
Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. 61 54
16467535 2006
41
Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. 54 61
16470820 2006
42
Increased prevalence of functional gastrointestinal disorders in panic disorder: clinical and theoretical implications. 54 61
16273019 2005
43
Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. 54 61
15830231 2005
44
Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls. 61 54
16046372 2005
45
The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. 61 54
15953484 2005
46
Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. 54 61
15939844 2005
47
Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. 54 61
15944741 2005
48
Association study of A2a adenosine receptor genetic polymorphism in panic disorder. 54 61
15774265 2005
49
Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder. 61 54
15722184 2005
50
Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa. 61 54
15523490 2005

Variations for Panic Disorder

Expression for Panic Disorder

Search GEO for disease gene expression data for Panic Disorder.

Pathways for Panic Disorder

Pathways related to Panic Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1 11.94 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
2 11.69 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
3
Show member pathways
11.65 SLC6A4 SLC6A2 COMT
4
Show member pathways
11.26 TPH2 SLC6A4 SLC6A2 MAOA
5
Show member pathways
10.94 SLC6A4 MAOA COMT
6 10.88 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
7
Show member pathways
10.84 MAOA COMT
8
Show member pathways
10.68 MAOA COMT
9 10.58 MAOA COMT
10 10.52 CCKBR CCK
11
Show member pathways
10.46 TPH2 SLC6A4 SLC6A2 MAOA HTR1A COMT

GO Terms for Panic Disorder

Cellular components related to Panic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 SLC6A4 SLC6A2 PTK7 HTR3A HTR2A HTR1A
2 integral component of presynaptic membrane GO:0099056 9.13 SLC6A4 HTR3A HTR2A
3 integral component of postsynaptic membrane GO:0099055 8.8 SLC6A4 HTR3A HTR2A

Biological processes related to Panic Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.2 PTK7 HTR3A HTR2A HTR1A CRH CCKBR
2 positive regulation of cell proliferation GO:0008284 9.97 HTR2A HTR1A CRH CCKBR CCK
3 chemical synaptic transmission GO:0007268 9.77 SLC6A2 HTR3A HTR2A HTR1A CRH
4 memory GO:0007613 9.74 SLC6A4 HTR2A CCK
5 response to estrogen GO:0043627 9.65 TPH2 CRH COMT
6 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.63 HTR2A CCKBR CCKAR
7 response to drug GO:0042493 9.63 TSPO SLC6A4 SLC6A2 HTR2A CRH COMT
8 adrenal gland development GO:0030325 9.61 TSPO CRH
9 vasoconstriction GO:0042310 9.59 SLC6A4 HTR1A
10 behavior GO:0007610 9.58 HTR2A HTR1A
11 catecholamine metabolic process GO:0006584 9.56 MAOA COMT
12 positive regulation of mitochondrial depolarization GO:0051901 9.55 TSPO CCK
13 neurotransmitter catabolic process GO:0042135 9.54 MAOA COMT
14 dopamine catabolic process GO:0042420 9.52 MAOA COMT
15 monoamine transport GO:0015844 9.51 SLC6A4 SLC6A2
16 neurotransmitter reuptake GO:0098810 9.49 SLC6A4 SLC6A2
17 positive regulation of behavioral fear response GO:2000987 9.43 CRH CCK
18 regulation of hormone secretion GO:0046883 9.4 HTR1A CCKAR
19 cholecystokinin signaling pathway GO:0038188 9.32 CCKBR CCKAR
20 regulation of serotonin secretion GO:0014062 9.26 HTR1A CRH
21 serotonin receptor signaling pathway GO:0007210 9.13 HTR3A HTR2A HTR1A
22 response to pain GO:0048265 8.92 TSPO SLC6A2 CRH COMT

Molecular functions related to Panic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.43 HTR3A HTR2A HTR1A
2 neurotransmitter:sodium symporter activity GO:0005328 9.32 SLC6A4 SLC6A2
3 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A4 SLC6A2
4 cholecystokinin receptor activity GO:0004951 8.96 CCKBR CCKAR
5 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Panic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....